From the Dallas Plastic Surgery Institute.
Plast Reconstr Surg. 2022 Apr 1;149(4):638e-645e. doi: 10.1097/PRS.0000000000009067.
The purpose of this special topic article is to explore the current state of outcomes-based literature related to breast implant illness and summarize the key understandings that emerge from the summation of existing studies. While implanted silicone devices are some of the most ubiquitous products in modern medicine, the safety of silicone breast implants has long remained under scientific scrutiny. In the era of social media and with breast implants once again under public scrutiny with the recent connection of texture silicone implants to breast implant-associated anaplastic large-cell lymphoma, the borders between breast implant illness and other implant-related diseases are becoming clouded in the public eye. The surgical management options for breast implant illness range from simple implant explantation alone to complete en bloc capsulectomies, or even secondary exploratory operations for additional capsulectomy in persistently symptomatic patients. In this review of outcomes-based studies related to breast implant illness, the authors found that a subset of patients improves with surgical intervention but limited evidence to inform most current surgical management practices. Further, the nature of this illness renders it difficult to study. A carefully designed, large, prospective, outcomes-based study is still required if an evidence-based and sound treatment approach for this condition is to be established.
本专题文章的目的是探讨当前与乳房植入病相关的基于结果的文献,并总结从现有研究总结中得出的关键认识。虽然植入式硅酮装置是现代医学中最普遍的产品之一,但硅酮乳房植入物的安全性长期以来一直受到科学审查。在社交媒体时代,随着最近纹理硅酮植入物与乳房植入物相关间变性大细胞淋巴瘤的联系,乳房植入病和其他与植入物相关的疾病之间的界限在公众眼中变得模糊。乳房植入病的手术治疗选择范围从单纯的植入物单纯切除术到完整的包膜切除术,甚至在持续有症状的患者中进行二次探查手术以进行额外的包膜切除术。在对与乳房植入病相关的基于结果的研究进行综述后,作者发现一部分患者的手术干预后有所改善,但目前的手术管理实践大多缺乏证据支持。此外,这种疾病的性质使其难以研究。如果要为这种疾病建立一种基于证据和合理的治疗方法,仍然需要进行精心设计、大规模、前瞻性、基于结果的研究。